DECRESCENDO: de-escalating chemotherapy in HER2-positive, estrogen receptor-negative, node-negative early breast cancer

被引：3

作者：

Debien, Veronique ^{[1
]}

Adam, Virginie ^{[2
]}

Coart, Elisabeth ^{[3
]}

Agostinetto, Elisa ^{[1
]}

Goulioti, Theodora ^{[2
]}

Molinelli, Chiara ^{[1
]}

Arahmani, Amal ^{[2
]}

Zoppoli, Gabriele ^{[4
,5
]}

Piccart, Martine ^{[1
]}

机构：

[1] Univ Libre Bruxelles ULB, Hop Univ Bruxelles HUB, Inst Jules Bordet, Brussels, Belgium

[2] Breast Int Grp, Brussels, Belgium

[3] IDDI, Louvain La Neuve, Belgium

[4] Univ Genoa, Dept Internal Med, Grp Oncol Italiano Ric Clin GOIRC, Genoa, Italy

[5] Osped Policlin San Martino IRCCS, Genoa, Italy

来源：

FUTURE ONCOLOGY | 2023年 / 19卷 / 24期

关键词：

breast cancer; de-escalation; HER2-enriched; HER2-positive; neoadjuvant; treatment optimization; FIXED-DOSE COMBINATION; PHASE-II TRIAL; OPEN-LABEL; SUBCUTANEOUS INJECTION; TRASTUZUMAB; PERTUZUMAB; MULTICENTER; LAPATINIB; EFFICACY; SAFETY;

D O I：

10.2217/fon-2022-1282

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The human epidermal growth factor receptor 2 (HER2)-enriched intrinsic subtype represents up to 75% of all HER2-positive hormone receptor (HR)-negative breast cancer (BC). Optimizing HER2-targeting therapy in this population might allow the omission of anthracycline-based chemotherapy, which is associated with potentially severe toxicities. DECRESCENDO (NCT04675827) is a large, multicenter, single-arm phase II trial in patients with HR-negative, HER2-positive, node-negative early BC evaluating a neoadjuvant pertuzumab and trastuzumab fixed-dose combination administered subcutaneously plus taxane-based chemotherapy followed by adjuvant treatment, adapted according to response to neoadjuvant therapy. The primary end point is the 3-year recurrence-free survival rate in patients with 'HER2-enriched' tumors and a pathological complete response. This flexible care substudy offers adjuvant treatment administration outside the hospital to some patients.

引用

页码：1655 / 1667

页数：13

共 38 条

[1] Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update [J].

Allison, Kimberly H. ;

Hammond, M. Elizabeth H. ;

Dowsett, Mitchell ;

McKernin, Shannon E. ;

Carey, Lisa A. ;

Fitzgibbons, Patrick L. ;

Hayes, Daniel F. ;

Lakhani, Sunil R. ;

Chavez-MacGregor, Mariana ;

Perlmutter, Jane ;

Perou, Charles M. ;

Regan, Meredith M. ;

Rimm, David L. ;

Symmans, W. Fraser ;

Torlakovic, Emina E. ;

Varella, Leticia ;

Viale, Giuseppe ;

Weisberg, Tracey F. ;

McShane, Lisa M. ;

Wolff, Antonio C. .

JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (12) :1346-+

[2]

von Minckwitz Gunter, 2017, N Engl J Med, V377, P122, DOI [10.1056/NEJMx170011, 10.1056/NEJMoa1703643]

[3] Long-term toxic effects of adjuvant chemotherapy in breast cancer [J].

Azim, H. A., Jr. ;

de Azambuja, E. ;

Colozza, M. ;

Bines, J. ;

Piccart, M. J. .

ANNALS OF ONCOLOGY, 2011, 22 (09) :1939-1947

[4] Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial [J].

Baselga, Jose ;

Bradbury, Ian ;

Eidtmann, Holger ;

Di Cosimo, Serena ;

de Azambuja, Evandro ;

Aura, Claudia ;

Gomez, Henry ;

Dinh, Phuong ;

Fauria, Karine ;

Van Dooren, Veerle ;

Aktan, Gursel ;

Goldhirsch, Aron ;

Chang, Tsai-Wang ;

Horvath, Zsolt ;

Coccia-Portugal, Maria ;

Domont, Julien ;

Tseng, Ling-Min ;

Kunz, Georg ;

Sohn, Joo Hyuk ;

Semiglazov, Vladimir ;

Lerzo, Guillermo ;

Palacova, Marketa ;

Probachai, Volodymyr ;

Pusztai, Lajos ;

Untch, Michael ;

Gelber, Richard D. ;

Piccart-Gebhart, Martine .

LANCET, 2012, 379 (9816) :633-640

[5] Local-regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial) [J].

Bellon, Jennifer R. ;

Guo, Hao ;

Barry, William T. ;

Dang, Chau T. ;

Yardley, Denise A. ;

Moy, Beverly ;

Marcom, P. Kelly ;

Albain, Kathy S. ;

Rugo, Hope S. ;

Ellis, Matthew ;

Wolff, Antonio C. ;

Carey, Lisa A. ;

Overmoyer, Beth A. ;

Partridge, Ann H. ;

Hudis, Clifford A. ;

Krop, Ian ;

Burstein, Harold J. ;

Winer, Eric P. ;

Tolaney, Sara M. .

BREAST CANCER RESEARCH AND TREATMENT, 2019, 176 (02) :303-310

[6] What Is the Real Impact of Estrogen Receptor Status on the Prognosis and Treatment of HER2-Positive Early Breast Cancer? [J].

Brandao, Mariana ;

Caparica, Rafael ;

Malorni, Luca ;

Prat, Aleix ;

Carey, Lisa A. ;

Piccart, Martine .

CLINICAL CANCER RESEARCH, 2020, 26 (12) :2783-2788

[7] Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib [J].

Carey, Lisa A. ;

Berry, Donald A. ;

Cirrincione, Constance T. ;

Barry, William T. ;

Pitcher, Brandelyn N. ;

Harris, Lyndsay N. ;

Ollila, David W. ;

Krop, Ian E. ;

Henry, Norah Lynn ;

Weckstein, Douglas J. ;

Anders, Carey K. ;

Singh, Baljit ;

Hoadley, Katherine A. ;

Iglesia, Michael ;

Cheang, Maggie Chon U. ;

Perou, Charles M. ;

Winer, Eric P. ;

Hudis, Clifford A. .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (06) :542-+

[8] Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis [J].

Cortazar, Patricia ;

Zhang, Lijun ;

Untch, Michael ;

Mehta, Keyur ;

Costantino, Joseph P. ;

Wolmark, Norman ;

Bonnefoi, Herve ;

Cameron, David ;

Gianni, Luca ;

Valagussa, Pinuccia ;

Swain, Sandra M. ;

Prowell, Tatiana ;

Loibl, Sibylle ;

Wickerham, D. Lawrence ;

Bogaerts, Jan ;

Baselga, Jose ;

Perou, Charles ;

Blumenthal, Gideon ;

Blohmer, Jens ;

Mamounas, Eleftherios P. ;

Bergh, Jonas ;

Semiglazov, Vladimir ;

Justice, Robert ;

Eidtmann, Holger ;

Paik, Soonmyung ;

Piccart, Martine ;

Sridhara, Rajeshwari ;

Fasching, Peter A. ;

Slaets, Leen ;

Tang, Shenghui ;

Gerber, Bernd ;

Geyer, Charles E., Jr. ;

Pazdur, Richard ;

Ditsch, Nina ;

Rastogi, Priya ;

Eiermann, Wolfgang ;

von Minckwitz, Gunter .

LANCET, 2014, 384 (9938) :164-172

[9]

Debien V, 2022, J CLIN ONCOL, V40

[10] Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study [J].

Gianni, Luca ;

Bisagni, Giancarlo ;

Colleoni, Marco ;

Del Mastro, Lucia ;

Zamagni, Claudio ;

Mansutti, Mauro ;

Zambetti, Milvia ;

Frassoldati, Antonio ;

De Fato, Raffaella ;

Valagussa, Pinuccia ;

Viale, Giuseppe .

LANCET ONCOLOGY, 2018, 19 (02) :249-256

← 1 2 3 4 →